The search for the HIV vaccine has been going on for a while now with companies working day and night to try and find a lasting solution to the HIV menace.
After years of trying and failing a company by the name IAVI and Scripps Research has today announced good news on the HIV Vaccine front following phase 1 clinical trial testing a novel vaccine.
According to initial reports, The vaccine showed great success in stimulating the production of very rare immune cells which are important to start the process of generating antibodies against the fast-mutating HIV. 97% of the participants who received the vaccine were able to elicit the targeted response.
“This study demonstrates proof of principle for a new vaccine concept for HIV, a concept that could be applied to other pathogens, as well,” says William Schief, PhD, a professor and immunologist at Scripps Research.
The vaccine is set for more clinical trials before it can be released for global use. Meanwhile, share with us your thoughts on the matter kindly.
Content created and supplied by: lemmymbelle (via Opera News )
Opera News is a free to use platform and the views and opinions expressed herein are solely those of the author and do not represent, reflect or express the views of Opera News. Any/all written content and images displayed are provided by the blogger/author, appear herein as submitted by the blogger/author and are unedited by Opera News. Opera News does not consent to nor does it condone the posting of any content that violates the rights (including the copyrights) of any third party, nor content that may malign, inter alia, any religion, ethnic group, organization, gender, company, or individual. Opera News furthermore does not condone the use of our platform for the purposes encouraging/endorsing hate speech, violation of human rights and/or utterances of a defamatory nature. If the content contained herein violates any of your rights, including those of copyright, and/or violates any the above mentioned factors, you are requested to immediately notify us using via the following email address operanews-external(at)opera.com and/or report the article using the available reporting functionality built into our Platform See More